Wei Perng1, Sheryl L Rifas-Shiman2, Joanne Sordillo2, Marie-France Hivert2,3, Emily Oken2,3,4. 1. Department of Epidemiology, Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, Colorado School of Public Health, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA. 2. Division of Chronic Disease Research Across the Lifecourse (CoRAL), Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA. 3. Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts, USA. 4. Department of Nutrition, T. H. Chan Harvard School of Public Health, Boston, Massachusetts, USA.
Abstract
OBJECTIVE: The purpose of this article is to characterize metabolomic profiles of four overweight/obesity (OWOB) and metabolic risk (MetRisk) phenotypes among 524 adolescents aged approximately 13 years. METHODS: A four-level phenotype variable (non-OWOB and low MetRisk, non-OWOB and high MetRisk, OWOB and low MetRisk, and OWOB and high MetRisk) was created using BMI percentile to define OWOB, and high versus low MetRisk was derived as the fourth versus first to third quartiles of a z score calculated as the average of five externally standardized z scores for waist circumference, homeostatic model assessment of insulin resistance, high-density lipoprotein, triglycerides, and systolic blood pressure. Then associations of nine metabolite patterns derived from principal components analysis with phenotype after accounting for age, sex, race, and pubertal status were evaluated. RESULTS: Five metabolite patterns differed with respect to phenotype: factor 1 consisted of long-chain fatty acids and was lower among non-OWOB and high MetRisk (-0.90 [95% CI: -1.39 to -0.42]) versus non-OWOB and low MetRisk (referent); factors 5 (branched-chain amino acids), 8 (diacylglycerols), and 9 (steroid hormones) were highest among OWOB and high MetRisk; and factor 7 (long-chain acylcarnitines) was higher among non-OWOB and high MetRisk (0.47 [95% CI: 0.04 to 0.91]) and lower among OWOB and low MetRisk (-0.36 [95% CI: -0.68 to -0.04]). CONCLUSIONS: Long-chain fatty acids, branched-chain amino acids, acylcarnitines, diacylglycerols, and steroid hormones differed by weight status and metabolic phenotype.
OBJECTIVE: The purpose of this article is to characterize metabolomic profiles of four overweight/obesity (OWOB) and metabolic risk (MetRisk) phenotypes among 524 adolescents aged approximately 13 years. METHODS: A four-level phenotype variable (non-OWOB and low MetRisk, non-OWOB and high MetRisk, OWOB and low MetRisk, and OWOB and high MetRisk) was created using BMI percentile to define OWOB, and high versus low MetRisk was derived as the fourth versus first to third quartiles of a z score calculated as the average of five externally standardized z scores for waist circumference, homeostatic model assessment of insulin resistance, high-density lipoprotein, triglycerides, and systolic blood pressure. Then associations of nine metabolite patterns derived from principal components analysis with phenotype after accounting for age, sex, race, and pubertal status were evaluated. RESULTS: Five metabolite patterns differed with respect to phenotype: factor 1 consisted of long-chain fatty acids and was lower among non-OWOB and high MetRisk (-0.90 [95% CI: -1.39 to -0.42]) versus non-OWOB and low MetRisk (referent); factors 5 (branched-chain amino acids), 8 (diacylglycerols), and 9 (steroid hormones) were highest among OWOB and high MetRisk; and factor 7 (long-chain acylcarnitines) was higher among non-OWOB and high MetRisk (0.47 [95% CI: 0.04 to 0.91]) and lower among OWOB and low MetRisk (-0.36 [95% CI: -0.68 to -0.04]). CONCLUSIONS: Long-chain fatty acids, branched-chain amino acids, acylcarnitines, diacylglycerols, and steroid hormones differed by weight status and metabolic phenotype.
Authors: Shaan S Naughton; Michael L Mathai; Deanne H Hryciw; Andrew J McAinch Journal: Prostaglandins Other Lipid Mediat Date: 2016-06-24 Impact factor: 3.072
Authors: Nicholette D Palmer; Robert D Stevens; Peter A Antinozzi; Andrea Anderson; Richard N Bergman; Lynne E Wagenknecht; Christopher B Newgard; Donald W Bowden Journal: J Clin Endocrinol Metab Date: 2014-11-25 Impact factor: 5.958
Authors: Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson Journal: Vital Health Stat 11 Date: 2002-05
Authors: Anna Viitasalo; Timo A Lakka; David E Laaksonen; Kai Savonen; Hanna-Maaria Lakka; Maija Hassinen; Pirjo Komulainen; Tuomo Tompuri; Sudhir Kurl; Jari A Laukkanen; Rainer Rauramaa Journal: Diabetologia Date: 2014-01-24 Impact factor: 10.122
Authors: So-Youn Shin; Eric B Fauman; Ann-Kristin Petersen; Jan Krumsiek; Rita Santos; Jie Huang; Matthias Arnold; Idil Erte; Vincenzo Forgetta; Tsun-Po Yang; Klaudia Walter; Cristina Menni; Lu Chen; Louella Vasquez; Ana M Valdes; Craig L Hyde; Vicky Wang; Daniel Ziemek; Phoebe Roberts; Li Xi; Elin Grundberg; Melanie Waldenberger; J Brent Richards; Robert P Mohney; Michael V Milburn; Sally L John; Jeff Trimmer; Fabian J Theis; John P Overington; Karsten Suhre; M Julia Brosnan; Christian Gieger; Gabi Kastenmüller; Tim D Spector; Nicole Soranzo Journal: Nat Genet Date: 2014-05-11 Impact factor: 38.330
Authors: Francisco J Rupérez; Gabriel Á Martos-Moreno; David Chamoso-Sánchez; Coral Barbas; Jesús Argente Journal: Nutrients Date: 2020-10-29 Impact factor: 5.717
Authors: Margot De Spiegeleer; Ellen De Paepe; Lieven Van Meulebroek; Inge Gies; Jean De Schepper; Lynn Vanhaecke Journal: Mol Med Date: 2021-11-06 Impact factor: 6.354
Authors: Thierry Comlan Marc Medehouenou; Cynthia Roy; Pierre-Yves Tremblay; Audray St-Jean; Salma Meziou; Gina Muckle; Pierre Ayotte; Michel Lucas Journal: Int J Circumpolar Health Date: 2021-12 Impact factor: 1.228
Authors: Antonio Paride Passaro; Pierluigi Marzuillo; Stefano Guarino; Federica Scaglione; Emanuele Miraglia Del Giudice; Anna Di Sessa Journal: World J Diabetes Date: 2021-12-15